ABSTRACT
To explore the thinking and working mode of clinical pharmacists of traditional Chinese medicine participating in clinical,the drug treatment was analyzed by an acute hyperkalemia patient suspected of CKD 5 caused by traditional Chinese medicine.This case is a CKD 5 patient.Since proteinuria was found for 8 years,bilateral lower limb edema was intermittent for 4 years,and the recurrence was aggravated for 1 week,the patient was admitted to the hospital.In the Department of Traditional Chinese Medicine,the patient received standard and reasonable antiplatelet,lipid regulation,kidney protection,anemia improvement,blood pressure reduction,and heart load reduction,Traditional Chinese medicine decoction,traditional Chinese patent medicines.The patient's condition improved,but the newly emerging hyperkalemia prolonged the patient's hospital stay.After the treatment of blood potassium lowering drugs,the blood potassium still increased repeatedly.For this reason,clinical Chinese pharmacists assisted clinicians to find out the factors that caused the repeated increase of blood potassium in combination with existing domestic and foreign literature.Finally,considering the high possibility of traditional Chinese medicine,they stopped using traditional Chinese medicine and continued to use blood potassium lowering drugs,and the blood potassium returned to normal.Hyperkalemia caused by traditional Chinese medicine is not common in clinical practice and often is ignored.It can be seen that clinical pharmacists can participate in pharmaceutical care to find adverse drug reactions as soon as possible and ensure the safety of drug use.
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE: We present a case of intravenous amiodarone-induced liver injury, pharmacy monitoring and its therapy. CASE SUMMARY: A 76-year-old male patient developed acute liver injury 24 h after starting intravenous amiodarone. His liver enzymes improved after discontinuing amiodarone and anti-inflammatory liver therapy, which used reduced glutathione, magnesium isoglycyrrhizinate and ademetionine1,4-butanedisulfonate for injection. WHAT IS NEW AND CONCLUSION: Amiodarone is a highly effective antiarrhythmic agent for the treatment and prevention of atrial and ventricular arrhythmias. Acute liver damage after intravenous amiodarone is rare but potentially harmful. Amiodarone loading should be adapted to the necessity of an immediate effect of the drug, and liver function should be monitored closely in critically ill patients. Timely stopped suspected drug and anti-inflammatory liver therapy may reduce the occurrence of drug-induced diseases.